Download PDF
Thromb Haemost 2019; 119(02): 328-339
DOI: 10.1055/s-0038-1676816
Stroke, Systemic or Venous Thromboembolism
Georg Thieme Verlag KG Stuttgart · New York

Antiplatelet Therapy versus Anticoagulation after Surgical Bioprosthetic Aortic Valve Replacement: A Systematic Review and Meta-Analysis

Kevin R. An
1   Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada
,
Emilie P. Belley-Cote
2   Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada
3   Division of Cardiology, McMaster University, Hamilton, Ontario, Canada
4   Population Health Research Institute, Hamilton, Ontario, Canada
,
Kevin J. Um
1   Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada
,
Saurabh Gupta
2   Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada
5   Division of Cardiac Surgery, McMaster University, Hamilton, Ontario, Canada
,
Graham R. McClure
1   Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada
,
Iqbal H. Jaffer
2   Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada
4   Population Health Research Institute, Hamilton, Ontario, Canada
5   Division of Cardiac Surgery, McMaster University, Hamilton, Ontario, Canada
,
Arjun Pandey
6   Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada
,
Jessica Spence
2   Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada
7   Department of Anesthesia, McMaster University, Hamilton, Ontario, Canada
,
Sake J. Van der Wall
8   Department of Thrombosis and Hemostasis, Leiden University Medical Centre, Leiden University, Leiden, The Netherlands
,
John W. Eikelboom
4   Population Health Research Institute, Hamilton, Ontario, Canada
9   Division of Hematology and Thromboembolism, McMaster University, Hamilton, Ontario, Canada
,
Richard P. Whitlock
2   Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada
4   Population Health Research Institute, Hamilton, Ontario, Canada
5   Division of Cardiac Surgery, McMaster University, Hamilton, Ontario, Canada
› Author Affiliations Funding None.
Further Information

Publication History

07 August 2018

06 November 2018

Publication Date:
07 January 2019 (online)

    Permissions and Reprints

Abstract

Background The optimal antithrombotic therapy after surgical bioprosthetic aortic valve replacement (BAVR) is uncertain. We conducted a systematic review and meta-analysis of observational studies and randomized controlled trials (RCTs) comparing antiplatelet therapy and anticoagulation in patients with surgical BAVR.

Methods We searched Cochrane CENTRAL, MEDLINE and EMBASE from inception to 3 November 2017 for studies evaluating antiplatelet therapy versus anticoagulation early after surgical BAVR. We performed title and abstract screening, full-text review, risk of bias evaluation and data collection independently and in duplicate. We evaluated overall quality of evidence using the Grading of Recommendations Assessment, Development and Evaluation framework, and pooled data using a random effects model.

Results We identified 2 RCTs (n = 397) and 5 observational studies (n = 2,012) meeting our eligibility criteria. The mean follow-up for all outcomes was 3 months in RCTs, and 10 months for observational studies. Antiplatelet compared with anticoagulant therapy demonstrated a trend towards fewer major bleeds in RCTs (relative risk [RR], 0.34; 95% confidence interval [CI], 0.11–1.04, p = 0.06, I 2 = 0%, low quality evidence), and significantly fewer major bleeds in observational studies (RR, 0.34; 95% CI, 0.20–0.58, p ≤ 0.0001, I 2 = 0%, very low quality evidence), but stroke, thromboembolism and mortality did not show a significant difference in either RCTs or observational studies.

Conclusion Antiplatelet therapy demonstrated reduced bleeding risk with no negative effects on stroke, thromboembolism or mortality compared with anticoagulation therapy after surgical BAVR. Our confidence in the results is reduced by the low quality of the available evidence.

Keywords

aspirin - warfarin - VKA - antithrombotic therapy - biological aortic valve replacement

Authors' Contributions

E.B.C., R.W., K.A., S.G. and J.W.E. were involved in study conception and design. K.A., K.U., A.P. and S.J.V. were involved in data collection. K.A., K.U. and G.M. were involved in analysis of data. E.B.C., K.A., S.G., G.M., R.W., I.J., J.S., J.W.E. and K.U. were involved in drafting of the manuscript. All authors were involved in revising and approving the final version of the manuscript.


Supplementary Material

 

  • References

  • 1 Gott VL, Alejo DE, Cameron DE. Mechanical heart valves: 50 years of evolution. Ann Thorac Surg 2003; 76 (06) S2230-S2239
    CrossrefPubMedGoogle Scholar
  • 2 Hammermeister K, Sethi GK, Henderson WG, Grover FL, Oprian C, Rahimtoola SH. Outcomes 15 years after valve replacement with a mechanical versus a bioprosthetic valve: final report of the Veterans Affairs randomized trial. J Am Coll Cardiol 2000; 36 (04) 1152-1158
    CrossrefPubMedGoogle Scholar
  • 3 Hoffmann G, Lutter G, Cremer J. Durability of bioprosthetic cardiac valves. Dtsch Arztebl Int 2008; 105 (08) 143-148
    PubMedGoogle Scholar
  • 4 Heras M, Chesebro JH, Fuster V. , et al. High risk of thromboemboli early after bioprosthetic cardiac valve replacement. J Am Coll Cardiol 1995; 25 (05) 1111-1119
    CrossrefPubMedGoogle Scholar
  • 5 Chakravarty T, Søndergaard L, Friedman J. , et al; RESOLVE; SAVORY Investigators. Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study. Lancet 2017; 389 (10087): 2383-2392
    CrossrefPubMedGoogle Scholar
  • 6 Nishimura RA, Otto CM, Bonow RO. , et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2017; 70 (02) 252-289
    CrossrefPubMedGoogle Scholar
  • 7 Baumgartner H, Falk V, Bax JJ. , et al; ESC Scientific Document Group. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2017; 38 (36) 2739-2791
    CrossrefPubMedGoogle Scholar
  • 8 Whitlock RP, Sun JC, Fremes SE, Rubens FD, Teoh KH. , American College of Chest Physicians. Antithrombotic and thrombolytic therapy for valvular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141 (2 Suppl): e576S-600S
    CrossrefPubMedGoogle Scholar
  • 9 Jamieson WR, Cartier PC, Allard M. , et al. Surgical management of valvular heart disease 2004. Can J Cardiol 2004; 20 (Suppl E): 7E-120E
    PubMedGoogle Scholar
  • 10 Vaughan P, Waterworth PD. An audit of anticoagulation practice among UK cardiothoracic consultant surgeons following valve replacement/repair. J Heart Valve Dis 2005; 14 (05) 576-582
    PubMedGoogle Scholar
  • 11 Colli A, Verhoye J-PP, Heijmen R. , et al; ACTION Registry Investigators. Antithrombotic therapy after bioprosthetic aortic valve replacement: ACTION Registry survey results. Eur J Cardiothorac Surg 2008; 33 (04) 531-536
    CrossrefPubMedGoogle Scholar
  • 12 Schaff HV. Should Bioprostheses be Anticoagulated? Paper presented at AATS 2013 Heart Valve Summit. Chicago, IL: 2013
    Google Scholar
  • 13 Colli A, Verhoye JP, Leguerrier A, Gherli T. Anticoagulation or antiplatelet therapy of bioprosthetic heart valves recipients: an unresolved issue. Eur J Cardiothorac Surg 2007; 31 (04) 573-577
    CrossrefPubMedGoogle Scholar
  • 14 Masri A, Gillinov AM, Johnston DM. , et al. Anticoagulation versus antiplatelet or no therapy in patients undergoing bioprosthetic valve implantation: a systematic review and meta-analysis. Heart 2017; 103 (01) 40-48
    CrossrefPubMedGoogle Scholar
  • 15 Mydin MI, Dimitrakakis G, Younis J, Nowell J, Athanasiou T, Kourliouros A. Optimal thromboprophylaxis following bioprosthetic aortic valve replacement: still a matter of debate?. Interact Cardiovasc Thorac Surg 2012; 15 (01) 109-114
    CrossrefPubMedGoogle Scholar
  • 16 Al-Atassi T, Toeg H, Ruel M. Should we anticoagulate after bioprosthetic aortic valve replacement?. Expert Rev Cardiovasc Ther 2013; 11 (12) 1649-1657
    CrossrefPubMedGoogle Scholar
  • 17 El-Husseiny M, Salhiyyah K, Raja SG, Dunning J. Should warfarin be routinely prescribed for the first three months after a bioprosthetic valve replacement?. Interact Cardiovasc Thorac Surg 2006; 5 (05) 616-623
    CrossrefPubMedGoogle Scholar
  • 18 Nowell J, Wilton E, Markus H, Jahangiri M. Antithrombotic therapy following bioprosthetic aortic valve replacement. Eur J Cardiothorac Surg 2007; 31 (04) 578-585
    CrossrefPubMedGoogle Scholar
  • 19 Stevens SM, Doty JR. New evidence on old drugs; warfarin versus aspirin after bioprosthetic aortic valve placement. Thromb Res 2017; 150: 102-103
    CrossrefPubMedGoogle Scholar
  • 20 Riaz H, Alansari SA, Khan MS. , et al. Safety and use of anticoagulation after aortic valve replacement with bioprostheses: a meta-analysis. Circ Cardiovasc Qual Outcomes 2016; 9 (03) 294-302
    CrossrefPubMedGoogle Scholar
  • 21 Rafiq S, Steinbrüchel DA, Lilleør NB. , et al. Antithrombotic therapy after bioprosthetic aortic valve implantation: warfarin versus aspirin, a randomized controlled trial. Thromb Res 2017; 150: 104-110
    CrossrefPubMedGoogle Scholar
  • 22 Aceves-Velázquez E, Vieyra-Herrera G, Rodríguez-Chávez L, Herrera-Alarcón V. Evaluation of the antithrombotic strategy in low thrombotic risk patients who underwent aortic valve replacement with a bioprosthesis [in Spanish]. Arch Cardiol Mex 2017; pii: S1405-9940(17)30070-8
    PubMedGoogle Scholar
  • 23 van der Wall SJ, Umans VAWM, Schotten J. , et al. Antithrombotic strategy after bioprosthetic aortic valve replacement in patients in sinus rhythm: evaluation of guideline implementation. Eur J Cardiothorac Surg 2016; 49 (04) 1157-1163
    CrossrefPubMedGoogle Scholar
  • 24 Booth A. PROSPERO's progress and activities 2012/13. Syst Rev 2013; 2 (01) 111
    CrossrefPubMedGoogle Scholar
  • 25 Covidence systematic review software, Veritas Health Innovation, Melbourne, Australia. Available at www.covidence.org . Accessed December 26, 2018
    PubMed
  • 26 Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014
    PubMed
  • 27 Higgins JPT, Altman DG, Gøtzsche PC. , et al; Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928
    CrossrefPubMedGoogle Scholar
  • 28 Busse JW, Guyatt GH. Tool to assess risk of bias in case control studies. Available at: https://www.evidencepartners.com/wp-content/uploads/2017/09/Tool-to-Assess-Risk-of-Bias-in-Case-Control-Studies.pdf
    PubMedGoogle Scholar
  • 29 Busse JW, Guyatt GH. Tool to assess risk of bias in cohort studies. Available at: https://methods.cochrane.org/bias/sites/methods.cochrane.org.bias/files/public/uploads/Tool%20to%20Assess%20Risk%20of%20Bias%20in%20Cohort%20Studies.pdf
    PubMedGoogle Scholar
  • 30 Guyatt G, Oxman AD, Akl EA. , et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011; 64 (04) 383-394
    CrossrefPubMedGoogle Scholar
  • 31 Colli A, Mestres CA, Castella M, Gherli T. Comparing warfarin to aspirin (WoA) after aortic valve replacement with the St. Jude Medical Epic heart valve bioprosthesis: results of the WoA Epic pilot trial. J Heart Valve Dis 2007; 16 (06) 667-671
    PubMedGoogle Scholar
  • 32 Colli A, Verhoye JP, Heijmen R, Antunes M. ; ACTION Investigators. Low-dose acetyl salicylic acid versus oral anticoagulation after bioprosthetic aortic valve replacement. Final report of the ACTION registry. Int J Cardiol 2013; 168 (02) 1229-1236
    CrossrefPubMedGoogle Scholar
  • 33 Gherli T, Colli A, Fragnito C. , et al. Comparing warfarin with aspirin after biological aortic valve replacement: a prospective study. Circulation 2004; 110 (05) 496-500
    CrossrefPubMedGoogle Scholar
  • 34 di Marco F, Grendene S, Feltrin G, Meneghetti D, Gerosa G. Antiplatelet therapy in patients receiving aortic bioprostheses: a report of clinical and instrumental safety. J Thorac Cardiovasc Surg 2007; 133 (06) 1597-1603
    CrossrefPubMedGoogle Scholar
  • 35 Brown ML, Park SJ, Sundt TM, Schaff HV. Early thrombosis risk in patients with biologic valves in the aortic position. J Thorac Cardiovasc Surg 2012; 144 (01) 108-111
    CrossrefPubMedGoogle Scholar
  • 36 Dalén M, Sartipy U, Cederlund K. , et al. Hypo-attenuated leaflet thickening and reduced leaflet motion in sutureless bioprosthetic aortic valves. J Am Heart Assoc 2017; 6 (08) e005251
    PubMedGoogle Scholar
  • 37 Connolly SJ. Anticoagulant-related bleeding and mortality. J Am Coll Cardiol 2016; 68 (23) 2522-2524
    CrossrefPubMedGoogle Scholar
  • 38 Steinberg BA, Simon DN, Thomas L. , et al; Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Investigators and Patients. Management of major bleeding in patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants compared with warfarin in clinical practice (from Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF II]). Am J Cardiol 2017; 119 (10) 1590-1595
    CrossrefPubMedGoogle Scholar
  • 39 Eikelboom JW, Connolly SJ, Hart RG. , et al. Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation. J Am Coll Cardiol 2013; 62 (10) 900-908
    CrossrefPubMedGoogle Scholar
  • 40 Cremer P, Barzilai B. Anticoagulation strategies after bioprosthetic valve replacement: what should we do?. Am Coll Cardiol 2016; 1-9
    PubMedGoogle Scholar